Open AccessThe intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells
Author(s) -
Nicholas G. Nickols,
Ekambaram Ganapathy,
Christine Nguyen,
Nathanael Kane,
Lin Lin,
Silvia Diaz-Perez,
Ramin Nazarian,
Colleen Mathis,
Carol Felix,
Vincent Basehart,
Nazy Zomorodian,
Jae Young Kwak,
Amar U. Kishan,
Christopher King,
Patrick A. Kupelian,
Matthew B. Rettig,
Michael L. Steinberg,
Minsong Cao,
Beatrice S. Knudsen,
FangI Chu,
Tahmineh Romero,
David Elashoff,
Robert E. Reiter,
Dörthe Schaue
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0249-8
Subject(s) - medicine , prostate cancer , myeloid , radiation therapy , prostatectomy , immune system , immunotherapy , prostate , oncology , cancer , immunology
Hundreds of ongoing clinical trials combine radiation therapy, mostly delivered as stereotactic body radiotherapy (SBRT), with immune checkpoint blockade. However, our understanding of the effect of radiotherapy on the intratumoral immune balance is inadequate, hindering the optimal design of trials that combine radiation therapy with immunotherapy. Our objective was to characterize the intratumoral immune balance of the malignant prostate after SBRT in patients.